Dr. Nmazuo Ozuah is a member of the Global Pediatric Hematology-Oncology Excellence (HOPE), and the Lymphoma Program at Texas Children's Cancer and Hematology Center. His main interest is improving treatment outcomes for children with cancer in resource-limited settings, in particular Sub-Saharan Africa.
Ozuah received his basic medical training in Nigeria. Motivated by the dismal outcomes of children with malignancies in his home country, he moved to the United States where he completed his pediatric residency training at Boston Children’s Hospital. This was followed by clinical fellowship training in pediatric hematology/oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute. During his fellowship he received additional training in clinical/translational research through the National Cancer Institute (NCI) sponsored Harvard Catalyst - Clinical and Translational Research Academy. His goal is to conduct high-quality clinical/translational research in pediatric lymphoid malignancies, which will translate to measurable improvements in the morbidity and mortality of childhood cancer patients in Sub-Saharan Africa.
He is currently serving Global HOPE in Malawi.
In 2018, Ozuah was awarded the Daniel D. Von Hoff Innovator Award at the American Association of Cancer Research (AACR)/American Society of Clinical Oncology (ASCO) Methods in Clinical Cancer Research conference. This award recognizes the most innovative and impactful protocol from a workshop attendee. Ozuah's proposal was on the feasibility of dose-intensive response-based chemotherapy for pediatric Hodgkin's lymphoma in Malawi.
American Board of Pediatrics